Antigen-displaying Lipid-enveloped PLGA Nanoparticles As Delivery Agents for a Plasmodium Vivax Malaria Vaccine

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Feb 14

PMID 22328935

Citations 53

Authors

James J Moon

Heikyung Suh

Mark E Polhemus

Christian F Ockenhouse

Anjali Yadava

Darrell J Irvine

Affiliations

Soon will be listed here.

Abstract

The parasite Plasmodium vivax is the most frequent cause of malaria outside of sub-Saharan Africa, but efforts to develop viable vaccines against P. vivax so far have been inadequate. We recently developed pathogen-mimicking polymeric vaccine nanoparticles composed of the FDA-approved biodegradable polymer poly(lactide-co-glycolide) acid (PLGA) "enveloped" by a lipid membrane. In this study, we sought to determine whether this vaccine delivery platform could be applied to enhance the immune response against P. vivax sporozoites. A candidate malaria antigen, VMP001, was conjugated to the lipid membrane of the particles, and an immunostimulatory molecule, monophosphoryl lipid A (MPLA), was incorporated into the lipid membranes, creating pathogen-mimicking nanoparticle vaccines (VMP001-NPs). Vaccination with VMP001-NPs promoted germinal center formation and elicited durable antigen-specific antibodies with significantly higher titers and more balanced Th1/Th2 responses in vivo, compared with vaccines composed of soluble protein mixed with MPLA. Antibodies raised by NP vaccinations also exhibited enhanced avidity and affinity toward the domains within the circumsporozoite protein implicated in protection and were able to agglutinate live P. vivax sporozoites. These results demonstrate that these VMP001-NPs are promising vaccines candidates that may elicit protective immunity against P. vivax sporozoites.

Citing Articles

Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review.

Wang J, Zhao Z, Wang Q, Shi J, Wong D, Cheung J Vaccines (Basel). 2025; 12(12.

PMID: 39771997 PMC: 11680411. DOI: 10.3390/vaccines12121335.

Lipid polymer hybrid nanoparticles against lung cancer and their application as inhalable formulation.

Kassaee S, Richard D, Ayoko G, Islam N Nanomedicine (Lond). 2024; 19(25):2113-2133.

PMID: 39143915 PMC: 11486133. DOI: 10.1080/17435889.2024.2387530.

Nanotechnology Platform for Advancing Vaccine Development against the COVID-19 Virus.

Chowdhury N, Kundu A Diseases. 2023; 11(4).

PMID: 38131983 PMC: 10742622. DOI: 10.3390/diseases11040177.

Understanding Fc function for rational vaccine design against pathogens.

Bowman K, Kaplonek P, McNamara R mBio. 2023; 15(1):e0303623.

PMID: 38112418 PMC: 10790774. DOI: 10.1128/mbio.03036-23.

A Glance on Nanovaccine: A Potential Approach for Disease Prevention.

Garg A, Agrawal R, Chopra H, Singh T, Chaudhary R, Tankara A Curr Pharm Biotechnol. 2023; 25(11):1406-1418.

PMID: 37861010 DOI: 10.2174/0113892010254221231006100659.

References

Cui Z, Patel J, Tuzova M, Ray P, Phillips R, Woodward J . Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles. Vaccine. 2004; 22(20):2631-40. DOI: 10.1016/j.vaccine.2003.12.013. View

Jegerlehner A, Storni T, Lipowsky G, Schmid M, Pumpens P, Bachmann M . Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol. 2003; 32(11):3305-14. DOI: 10.1002/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J. View

Vogel G . Infectious disease. New map illustrates risk from the 'other' malaria. Science. 2010; 329(5992):618. DOI: 10.1126/science.329.5992.618. View

Ballou W . The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol. 2009; 31(9):492-500. DOI: 10.1111/j.1365-3024.2009.01143.x. View

Udhayakumar V, Saekhou A, Fang S, Jue D, Wohlhueter R, Lal A . Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC). Vaccine. 1998; 16(9-10):982-8. DOI: 10.1016/s0264-410x(97)00290-9. View

Nutt S, Tarlinton D . Germinal center B and follicular helper T cells: siblings, cousins or just good friends?. Nat Immunol. 2011; 12(6):472-7. DOI: 10.1038/ni.2019. View

Kasturi S, Skountzou I, Albrecht R, Koutsonanos D, Hua T, Nakaya H . Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011; 470(7335):543-7. PMC: 3057367. DOI: 10.1038/nature09737. View

Demento S, Bonafe N, Cui W, Kaech S, Caplan M, Fikrig E . TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J Immunol. 2010; 185(5):2989-97. PMC: 3753007. DOI: 10.4049/jimmunol.1000768. View

Price R, Tjitra E, Guerra C, Yeung S, White N, Anstey N . Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2008; 77(6 Suppl):79-87. PMC: 2653940. View

10.

Otten G, Schaefer M, Greer C, Calderon-Cacia M, Coit D, Kazzaz J . Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles. J Virol. 2003; 77(10):6087-92. PMC: 154004. DOI: 10.1128/jvi.77.10.6087-6092.2003. View

11.

Liu W, Chen Y . High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins. Eur J Immunol. 2005; 35(2):505-14. DOI: 10.1002/eji.200425749. View

12.

McHeyzer-Williams L, McHeyzer-Williams M . Antigen-specific memory B cell development. Annu Rev Immunol. 2005; 23:487-513. DOI: 10.1146/annurev.immunol.23.021704.115732. View

13.

Moon J, Suh H, Li A, Ockenhouse C, Yadava A, Irvine D . Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci U S A. 2012; 109(4):1080-5. PMC: 3268296. DOI: 10.1073/pnas.1112648109. View

14.

Liu H, Kwong B, Irvine D . Membrane anchored immunostimulatory oligonucleotides for in vivo cell modification and localized immunotherapy. Angew Chem Int Ed Engl. 2011; 50(31):7052-5. PMC: 3166645. DOI: 10.1002/anie.201101266. View

15.

Johnston R, Poholek A, DiToro D, Yusuf I, Eto D, Barnett B . Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science. 2009; 325(5943):1006-10. PMC: 2766560. DOI: 10.1126/science.1175870. View

16.

Yadava A, Sattabongkot J, Washington M, Ware L, Majam V, Zheng H . A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect Immun. 2006; 75(3):1177-85. PMC: 1828583. DOI: 10.1128/IAI.01667-06. View

17.

Bell B, Wood J, Bansal R, Ragab H, Cargo 3rd J, Washington M . Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax. Vaccine. 2009; 27(9):1448-53. DOI: 10.1016/j.vaccine.2008.12.027. View

18.

Jewell C, Bustamante Lopez S, Irvine D . In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Proc Natl Acad Sci U S A. 2011; 108(38):15745-50. PMC: 3179077. DOI: 10.1073/pnas.1105200108. View

19.

Reddy S, van der Vlies A, Simeoni E, Angeli V, Randolph G, ONeil C . Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007; 25(10):1159-64. DOI: 10.1038/nbt1332. View

20.

Charoenvit Y, Collins W, Jones T, Millet P, Yuan L, Campbell G . Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science. 1991; 251(4994):668-71. DOI: 10.1126/science.1704150. View